Crinetics Pharmaceuticals, Inc. financial data

Symbol
CRNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10222 Barnes Canyon Road, Bldg. #2, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.39K % +0.97%
Debt-to-equity 15 % +44.4%
Return On Equity -42.5 % +19.1%
Return On Assets -37 % +22.4%
Operating Margin 1.38M %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78.9M shares +46%
Common Stock, Shares, Outstanding 78.5M shares +45.5%
Entity Public Float 1B USD 0%
Common Stock, Value, Issued 881K USD
Weighted Average Number of Shares Outstanding, Basic 72.3M shares +34.1%
Weighted Average Number of Shares Outstanding, Diluted 72.3M shares +34.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 4.74M USD +339%
Revenue from Contract with Customer, Excluding Assessed Tax 640K USD -76.1%
Research and Development Expense 183M USD +30.6%
General and Administrative Expense 66.7M USD +45.5%
Operating Income (Loss) -248M USD -36.3%
Nonoperating Income (Expense) 18.4M USD +172%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -215M USD -30.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -235M USD -34.3%
Earnings Per Share, Basic -3.77 USD/shares -15.3%
Earnings Per Share, Diluted -3.77 USD/shares -15.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 396M USD +861%
Cash, Cash Equivalents, and Short-term Investments 901M USD +204%
Other Assets, Current 3.56M USD +8.18%
Assets, Current 917M USD +200%
Property, Plant and Equipment, Net 11.9M USD +263%
Operating Lease, Right-of-Use Asset 45.8M USD +3238%
Other Assets, Noncurrent 2M USD 0%
Assets 978M USD +212%
Accounts Payable, Current 10.8M USD +82.5%
Liabilities, Current 51.8M USD +96.7%
Operating Lease, Liability, Noncurrent 46.7M USD +2580%
Liabilities 103M USD +206%
Common Stocks, Including Additional Paid in Capital 1.6B USD +108%
Accumulated Other Comprehensive Income (Loss), Net of Tax 150K USD
Retained Earnings (Accumulated Deficit) -721M USD -48.5%
Stockholders' Equity Attributable to Parent 875M USD +212%
Liabilities and Equity 978M USD +212%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.9M USD -29.8%
Net Cash Provided by (Used in) Financing Activities 394M USD +81217%
Net Cash Provided by (Used in) Investing Activities 309K USD -99.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 78.5M shares +45.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 341M USD +3902%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 397M USD +835%
Deferred Tax Assets, Valuation Allowance 185M USD +46.8%
Deferred Tax Assets, Gross 195M USD +54%
Operating Lease, Liability 52.5M USD +1761%
Depreciation 1.1M USD +10%
Payments to Acquire Property, Plant, and Equipment 1.33M USD +8225%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -233M USD -32.6%
Lessee, Operating Lease, Liability, to be Paid 83.6M USD +2609%
Property, Plant and Equipment, Gross 17.3M USD +127%
Operating Lease, Liability, Current 5.79M USD +437%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.47M USD +757%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.17M USD +226%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.1M USD +11642%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.8M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.95M USD +69%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7M USD
Operating Lease, Payments 300K USD -66.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 46.3M USD +51.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%